Document Type

Article

Publication Date

1-1-2022

Publication Title

PLoS One

Keywords

JGM, Humans, Methicillin-Resistant Staphylococcus aureus, Staphylococcus aureus, Anti-Bacterial Agents, Virulence, Probiotics, Staphylococcal Infections, Microbial Sensitivity Tests

JAX Source

PLoS One. 2022;17(12):e0276795.

Volume

17

Issue

12

First Page

0276795

ISSN

1932-6203

PMID

36520793

DOI

https://doi.org/10.1371/journal.pone.0276795

Grant

This project is supported by the Department of Defense W81XWH-18-1-0229 and National Institutes of Health (DP2 GM126893-01, K22 AI119231-01, and 1 R21 AR075174). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract

The prevalence and virulence of pathogens such as methicillin-resistant Staphylococcus (S.) aureus (MRSA), which can cause recurrent skin infections, are of significant clinical concern. Prolonged antibiotic exposure to treat or decolonize S. aureus contributes to development of antibiotic resistance, as well as depletion of the microbiome, and its numerous beneficial functions. We hypothesized an engineered skin probiotic with the ability to selectively deliver antimicrobials only in the presence of the target organism could provide local bioremediation of pathogen colonization. We constructed a biosensing S. epidermidis capable of detecting the presence of S. aureus quorum sensing autoinducer peptide and producing lysostaphin in response. Here, we demonstrate in vitro activity of this biosensor and present and discuss challenges to deployment of this and other engineered topical skin probiotics.

Comments

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Download

Share

COinS